Cilengitide in Treating Children With Refractory Primary Brain Tumors

Inclusion Criteria

• •Patients with histological diagnosis of primary CNS tumor and evidence that the tumor is recurrent or progressive and refractory to standard therapy, including histologically benign CNS tumors (e.g. low-grade glioma); clinical and radiographic evidence of a brain stem or optic pathway glioma is required in the absence of histologic diagnosis
• •Karnofsky or Modified Lansky Score ≥ 50%
• •Patients with neurological deficits should have deficits that are stable for ≥ 1 week prior to study entry
• •Chemotherapy: Patients with evidence of recovery from prior therapy; no investigational agent, including biologic agent, within two (2) weeks of study entry; at least six (6) weeks from nitrosourea agent to study entry; at least four (4) weeks from any myelosuppressive therapy to study entry
• •Bone Marrow Transplant: Greater than six (6) months prior to study entry
• •XRT: At least six (6) weeks from prior radiation therapy to study entry; greater than three (3) months from prior craniospinal irradiation (\> 24 Gy) or total body irradiation to study entry; greater than two (2) weeks from local palliative irradiation to study entry
• •Anti-convulsants: Patients will be eligible for this study even if they are receiving anti-convulsants
• •Growth factors: Off all colony forming growth factor(s) \> one (1) week prior to study entry (G-CSF, GM-CSF, erythropoietin)
• •Corticosteroids: Patients receiving corticosteroids must be receiving a stable dose for ≥ one (1) week prior to study entry
• •ANC \> 1,000/μl
• •Platelets \> 100,000/μl (transfusion independent)
• •Hemoglobin \> 8.0 g/dl (may be transfused)
• •Patients with bone marrow involvement may be eligible
• •Creatinine \< 1.5 times normal range for age
• •GFR \> 70 ml/min/1.73m\^2
• •Total bilirubin ≤ upper limit of normal for age
• •SGPT (ALT) and SGOT (AST) \< 2.5 times upper limit of normal
• •Cilengitide was teratogenic when tested in animals; as such, female patients of childbearing potential must have a negative serum or urine pregnancy test prior to study entry; female patients must avoid breast feeding while on study
• •Patients of childbearing potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study
• •Signed informed consent according to institutional guidelines must be obtained prior to patient registration